Forbes - NEW YORK (Thomson Financial) - Isis Pharmaceuticals Inc. Friday said it would receive up to $9.9 million from CHDI Inc. to develop a drug treatment for Huntington's Disease. CHDI, a nonprofit foundation pursuing treament for Huntington's, will ...